Quantcast

Accuray Incorporated’s CyberKnife® M6(TM) System Receives Shonin Approval

March 27, 2014

Latest CyberKnife technology now available in Japan

SUNNYVALE, Calif., March 27, 2014 /PRNewswire/ — Accuray Incorporated (Nasdaq: ARAY) announced today it received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the CyberKnife® M6(TM) System to treat radiation therapy patients. The system, which will be marketed in Japan as the “CyberKnife M6 Series,” offers the widest range of motion and highest-precision conformal delivery available and enables patients to lie comfortably and breathe freely while receiving precise, high dose radiation therapy in a relatively short number of treatments, reducing side effects and preserving quality of life.

The CyberKnife System enables physicians to precisely maximize dose, minimize side effects and maximize patient comfort. It continues to provide patients in Japan with the latest advances in CyberKnife motion management technology. It automatically adjusts the beam for target movement, enabling reduced margins and minimizing radiation exposure to healthy tissue and critical organs. Patients treated with the CyberKnife System will not experience the discomfort of breath-holding, abdominal compression, breathing apparatus, or metal head-frames typically associated with other radiation therapy devices.

“At Accuray, we understand the priority that our customers place on advanced medical technology and patient comfort,” said Juki Hozumi, president and general manager of Japan at Accuray. “We are committed to excellence in service, support and education that will enable our customers to optimize their use of our leading-edge tumor treatments long-term.”

“This marks a key milestone in our strategic growth plan for the market in Japan,” said Joshua H. Levine, president and chief executive officer of Accuray. “We are very pleased to provide the latest CyberKnife technology to our customers and their patients in Japan. The CyberKnife M6 Series offers advantages of increased clinical flexibility, greatly reduced treatment times and ease of use for clinicians, while providing patients the most precise tumor treatment available.”

In July 2010, Accuray was granted Shonin approval of the CyberKnife G4 System for use in Japan in the treatment of tumors in the body, inclusive of the head and neck. In 2012, Accuray received Shonin approval to market the CyberKnife VSI(TM) System for robotic radiosurgery.

About the CyberKnife System
As the first, and only, robotic full-body radiosurgery system available today, the CyberKnife System is optimized to deliver stereotactic radiosurgery and stereotactic body radiation therapy (SRS/SBRT) non-invasively throughout the body. Its ability to track and automatically correct for tumor motion during treatment enables delivery of high doses of radiation with extreme accuracy, providing customized treatments to meet each patient’s needs.

About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company’s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, clinical applications, clinical performance, clinical results, patient treatment times and outcomes, market acceptance and longevity of the company’s products, and Accuray’s leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from under the heading “Risk Factors” in Accuray’s report on Form 10-K, which was filed on August 29,( )2013, the company’s report on Form 10-Q, which was filed on February 7, 2014, and as updated periodically by the company’s other filings.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. Accuray assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

SOURCE Accuray Incorporated


Source: PR Newswire



comments powered by Disqus